Title: Comment submitted by GlaxoSmithKline
Title: Comment submitted by GlaxoSmithKline (2)
Abstract: Facility Revisions and Emissions Revisions.
Details Information
Attachments:
Comment submitted by GlaxoSmithKline
View Attachment:Comment submitted by GlaxoSmithKline (2)
View Attachment:Comments
Related Documents